Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical
management of cancer. The recent approvals of brentuximab vedotin and ado-trastuzumab …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

Antibody therapeutics have revolutionized the treatment of cancer over the past two
decades. Antibodies that specifically bind tumor surface antigens can be effective …

Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

The concept of exploiting the specific binding properties of monoclonal antibodies as a
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …

Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.
Monoclonal antibodies against antigens on cancer cells offer an alternative tumor‐selective …

The convergence of advanced understanding of biology with chemistry has led to a
resurgence in the development of antibody-drug conjugates (ADCs), especially with two …

Antibody drug conjugates (ADCs) have progressed from hypothesis to approved
therapeutics in less than 30 years, and the technologies available to modify both the …